A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 9, 2005, Pages 1097-1104

  Takabatake, Noriaki ^b   Sata, Makoto ^a   Inoue, Sumito ^b   Shibata, Yoko ^b   Abe, Shuichi ^b   Wada, Toshihiro ^b   Machiya, Jun Ichi ^b   Ji, Guijin ^b   Matsuura, Tadashi ^b   Takeishi, Yasuchika ^b   Muramatsu, Masaaki ^b   Kubota, Isao ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b NONE

Author keywords

Analysis of covariance; Body weight loss; Chronic obstructive pulmonary disease; Single nucleotide polymorphism; sPLA2 IID gene

Indexed keywords

AMINO ACID; PHOSPHOLIPASE A2;

ANALYSIS OF VARIANCE; ARTICLE; BIOTECHNOLOGY; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; FISHER EXACT TEST; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; WEIGHT LOSS;

EID: 30344473029     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200503-319OC     Document Type: Article

References (34)

1. Murray CJL, Lopez AD. Evidence-based health policy: lessons from the global burden of disease study. Science 1996;274:740-743.
2. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, for the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
3. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J 2003;46:5S-13S.
4. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580.
5. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. Eur Respir J 2003;46:2S-4S.
6. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002;121:127S-130S.
7. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360.
8. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-1224.
9. Takabatake N, Nakamura H, Minamihaba O, Inage M, Inoue S, Kagaya S, Yamaki M, Tomoike H. A novel pathophysiologic phenomenon in cachexic patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability. Am J Respir Crit Care Med 2001;163:1314-1319.
10. Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, Tomoike H. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1179-1184.
11. Takabatake N, Nakamura H, Abe S, Hino T, Saito H, Yuki H, Kato S, Tomoike H. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1215-1219.
12. Schols AM, Slangen J, Volovics L, Wouters EF.Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791-1797.
13. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856-1861.
14. Argiles JM, Lopez-Soriano J, Busquets S, Lopez-Soriano FJ. Journey from cachexia to obesity by TNF. FASEB J 1997;11:743-751.
15. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-1156.
16. Engelen MP, Schols AM, Lamers RJ, Wouters EF. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr 1999;18:275-280.
17. Silverman EK, Speizer FE, Weiss ST, Chapman HA Jr, Schuette A, Campbell EJ, Reilly JJ Jr, Ginns LC, Drazen JM. Familial aggregation of severe, early-onset COPD: candidate gene approaches. Chest 2000;117:273S-274S.
18. Silverman EK, Chapman HA, Drazen JM,Weiss ST, Rosner B, Campbell EJ, O'Donnell WJ, Reilly JJ, Ginns L, Mentzer S, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770-1778.
19. 2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med 2001;1:739-754.
20. 2 in patients with septic shock and trauma. Intensive Care Med 1994;20:555-561.
21. 2, cytokines and eicosanoids in patients with burns. Burns 1995;21:422-426.
22. 2 as an index of disease activity in rheumatoid arthritis: prospective double blind study of 212 patients. J Rheumatol 1996;23:1162-1166.
23. 2 in serum and colonic mucosa in ulcerative colitis. Scand J Clin Lab Invest 1999;59:279-287.
24. 2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol 2003;131:153-163.
25. 2. J Biochem (Tokyo) 2002;131:285-292.
26. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S120.
27. Japanese Society of Chest Disease. Standards of pulmonary function tests for Japanese. Jpn J Thorac Dis 1993;31:Appendix.
28. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999;14:143-149.
29. Wildt AR, Ahtola OT.Analysis of covariance. In: Hills, B, editor. Quantitative Applications in the Social Sciences, series 12. Thousand Oaks, CA: Sage Publications; 1978.
30. Ishizaki J, Suzuki N, Higashino K, Yokota Y, Ono T, Kawamoto K, Fujii N, Arita H, Hanasaki K. Cloning and characterization of novel mouse and human secretory phospholipase A(2)s. J Biol Chem 1999;274:24973-24979.
31. Murakami M, Yoshihara K, Shimbara S, Sawada M, Inagaki N, Nagai H, Naito M, Tsuruo T, Moon TC, Chang HW, et al. Group IID heparin-binding secretory phospholipase A(2) is expressed in human colon carcinoma cells and human mast cells and up-regulated in mouse inflammatory tissues. Eur J Biochem 2002;269:2698-2707.
32. Suzuki N, Ishizaki J, Yokota Y, Higashino K, Ono T, Ikeda M, Fujii N, Kawamoto K, Hanasaki K. Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s. J Biol Chem 2000;275:5785-5793.
33. Fabbri L, Peters SP, Pavord I, Wenzel SE, Lazarus SC, Macnee W, Lemaire F, Abraham E. Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004. Am J Respir Crit Care Med 2005;171:686-698.
34. Tobin MJ. Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2003. Am J Respir Crit Care Med 2004;169:301-313.